These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 17201179)

  • 21. The effect of intravesical instillation of antifibrinolytic agents on bacillus Calmette-Guerin treatment of superficial bladder cancer: a pilot study.
    Pan CW; Shen ZJ; Ding GQ
    J Urol; 2008 Apr; 179(4):1307-11; discussion 1311-2. PubMed ID: 18289576
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intravesical instillation therapy with bacillus Calmette-Guérin for superficial bladder cancer: study of the mechanism of bacillus Calmette-Guérin immunotherapy.
    Shintani Y; Sawada Y; Inagaki T; Kohjimoto Y; Uekado Y; Shinka T
    Int J Urol; 2007 Feb; 14(2):140-6. PubMed ID: 17302571
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cell proliferation and DNA content in rat urothelial lesions after repeat intravesical instillations of mitomycin C and bacillus Calmette-Guérin.
    Oliveira P; Palmeira C; Colaço A; De la Cruz P LF; Lopes C
    Urol Int; 2008; 80(1):90-7. PubMed ID: 18204241
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Editorial comment on: Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder cancer.
    Evans CP
    Eur Urol; 2007 Oct; 52(4):1129-30. PubMed ID: 17383082
    [No Abstract]   [Full Text] [Related]  

  • 25. Clinical utility of fluorescent in situ hybridization for the surveillance of bladder cancer patients treated with bacillus Calmette-Guérin therapy.
    Mengual L; Marín-Aguilera M; Ribal MJ; Burset M; Villavicencio H; Oliver A; Alcaraz A
    Eur Urol; 2007 Sep; 52(3):752-9. PubMed ID: 17379395
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Quality of life and adverse events in patients with nonmuscle invasive bladder cancer receiving adjuvant treatment with BCG, MMC, or chemohyperthermia.
    González-Padilla DA; González-Díaz A; Guerrero-Ramos F; Rodríguez-Serrano A; García-Jarabo E; Corona-laPuerta M; Rodríguez-Antolín A; Villacampa-Aubá F
    Urol Oncol; 2021 Jan; 39(1):76.e9-76.e14. PubMed ID: 32753359
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Is intravesical bacillus Calmette-Guérin better than mitomycin for intermediate-risk bladder cancer?
    Dalbagni G
    Eur Urol; 2009 Aug; 56(2):257-8; discussion 258-9. PubMed ID: 19427109
    [No Abstract]   [Full Text] [Related]  

  • 28. [A comparative study of BCG and mitomycin C in superficial carcinomas of the bladder].
    Iavarone C; Minocchi L; Arecchi S; Nicolucci D; Porcelli C; D'orazi V; Greco L; Stio F; Martino G; Messinetti S
    G Chir; 1996 May; 17(5):289-91. PubMed ID: 8755233
    [No Abstract]   [Full Text] [Related]  

  • 29. Can early single dose instillation of epirubicin improve bacillus Calmette-Guerin efficacy in patients with nonmuscle invasive high risk bladder cancer? Results from a prospective, randomized, double-blind controlled study.
    Cai T; Nesi G; Tinacci G; Zini E; Mondaini N; Boddi V; Mazzoli S; Bartoletti R
    J Urol; 2008 Jul; 180(1):110-5. PubMed ID: 18485394
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Patterns of recurrence and outcomes following induction bacillus Calmette-Guerin for high risk Ta, T1 bladder cancer.
    Lerner SP; Tangen CM; Sucharew H; Wood D; Crawford ED
    J Urol; 2007 May; 177(5):1727-31. PubMed ID: 17437798
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment options and results of adjuvant treatment in nonmuscle-invasive bladder cancer (NMIBC) during the Bacillus Calmette-Guérin shortage.
    Fankhauser CD; Teoh JY; Mostafid H
    Curr Opin Urol; 2020 May; 30(3):365-369. PubMed ID: 32141939
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intravesical bacillus Calmette-Guérin therapy for T1 superficial bladder cancer.
    Demkow T; Alter A; Wiechno P
    Urol Int; 2008; 80(1):74-9. PubMed ID: 18204238
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [ BCG-immunotherapy and bladder cancer].
    Rischmann P
    Prog Urol; 2008 May; 18 Suppl 5():S93. PubMed ID: 18585633
    [No Abstract]   [Full Text] [Related]  

  • 34. [Sequential treatment with Mitomycin C and BCG in non muscle invasive bladder cancer.].
    Chantada-Abal V; Chantada-Tirado C; Lamas-Díaz L; Caramés-Masana F; Villegas-Piguave AD; Villar-Vázquez N
    Arch Esp Urol; 2018 May; 71(4):453-457. PubMed ID: 29745935
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bladder contracture: review for intravesical bacillus Calmette-Guerin complication.
    Hameed A; Sezian N; Thwaini A
    Can J Urol; 2007 Dec; 14(6):3745-9. PubMed ID: 18163926
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Treatment of non-muscle invasive bladder tumours by instillations of mitomycin C and BCG: a survey on French urologists by the French Urological Association].
    Descazeaud A; Mignard JP; Davin JL; Irani J
    Prog Urol; 2009 Oct; 19(9):624-31. PubMed ID: 19800553
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Management of Ta, T1, and in situ bladder carcinoma: what is new?].
    Irani J
    Prog Urol; 2008 May; 18 Suppl 5():S94-8. PubMed ID: 18585634
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of previous bacille Calmette-Guérin failure pattern on subsequent response to bacille Calmette-Guérin plus interferon intravesical therapy.
    Gallagher BL; Joudi FN; Maymí JL; O'Donnell MA
    Urology; 2008 Feb; 71(2):297-301. PubMed ID: 18308107
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mitomycin C from birth to adulthood.
    Serretta V; Scalici Gesolfo C; Alonge V; Di Maida F; Caruana G
    Urologia; 2016 Oct; 83(Suppl 2):2-6. PubMed ID: 27716885
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Quality of life in patients with non-muscle invasive bladder tumor undergoing adjuvant intravesical treatment.
    Panach-Navarrete J; Devís-Peiró A; Lloret-Durà MA; Sánchez-Gimeno S; Murcia-Díez E; Martínez-Jabaloyas JM
    Actas Urol Esp (Engl Ed); 2023; 47(6):360-368. PubMed ID: 36746347
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.